These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 8104327

  • 1. Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor in vitro and in vivo.
    Lofts FJ, Hurst HC, Sternberg MJ, Gullick WJ.
    Oncogene; 1993 Oct; 8(10):2813-20. PubMed ID: 8104327
    [Abstract] [Full Text] [Related]

  • 2. Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation.
    Burke CL, Lemmon MA, Coren BA, Engelman DM, Stern DF.
    Oncogene; 1997 Feb 13; 14(6):687-96. PubMed ID: 9038376
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of p185neu kinase activity and cellular transformation by co-expression of a truncated neu protein.
    Qian X, O'Rourke DM, Zhao H, Greene MI.
    Oncogene; 1996 Nov 21; 13(10):2149-57. PubMed ID: 8950982
    [Abstract] [Full Text] [Related]

  • 4. Neu and its ligands: from an oncogene to neural factors.
    Peles E, Yarden Y.
    Bioessays; 1993 Dec 21; 15(12):815-24. PubMed ID: 7908191
    [Abstract] [Full Text] [Related]

  • 5. Downregulation of the early genomic growth factor response in neu oncogene-transformed cells.
    Sistonen L, Koskinen PJ, Lehväslaiho H, Lehtola L, Bravo R, Alitalo K.
    Oncogene; 1990 Jun 21; 5(6):815-21. PubMed ID: 1972791
    [Abstract] [Full Text] [Related]

  • 6. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo.
    Drebin JA, Link VC, Greene MI.
    Oncogene; 1988 Apr 21; 2(4):387-94. PubMed ID: 2896329
    [Abstract] [Full Text] [Related]

  • 7. Mutation of the human neu protein facilitates down-modulation by monoclonal antibodies.
    van Leeuwen F, van de Vijver MJ, Lomans J, van Deemter L, Jenster G, Akiyama T, Yamamoto T, Nusse R.
    Oncogene; 1990 Apr 21; 5(4):497-503. PubMed ID: 1970152
    [Abstract] [Full Text] [Related]

  • 8. Specific locations of hydrophilic amino acids in constructed transmembrane ligands of the platelet-derived growth factor beta receptor.
    Freeman-Cook LL, Edwards AP, Dixon AM, Yates KE, Ely L, Engelman DM, Dimaio D.
    J Mol Biol; 2005 Jan 28; 345(4):907-21. PubMed ID: 15588835
    [Abstract] [Full Text] [Related]

  • 9. Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in 3T3 cells.
    Yu DH, Hung MC.
    Oncogene; 1991 Nov 28; 6(11):1991-6. PubMed ID: 1682865
    [Abstract] [Full Text] [Related]

  • 10. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation.
    Weiner DB, Liu J, Cohen JA, Williams WV, Greene MI.
    Nature; 1989 May 18; 339(6221):230-1. PubMed ID: 2654648
    [Abstract] [Full Text] [Related]

  • 11. Reexpression of neu-encoded oncoprotein counteracts the tumor-suppressing but not the metastasis-suppressing function of E1A.
    Yu D, Shi D, Scanlon M, Hung MC.
    Cancer Res; 1993 Dec 01; 53(23):5784-90. PubMed ID: 7902209
    [Abstract] [Full Text] [Related]

  • 12. Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein.
    Weiner DB, Kokai Y, Wada T, Cohen JA, Williams WV, Greene MI.
    Oncogene; 1989 Oct 01; 4(10):1175-83. PubMed ID: 2571965
    [Abstract] [Full Text] [Related]

  • 13. Structural and functional domains critical for constitutive activation of the HGF-receptor (Met).
    Zhen Z, Giordano S, Longati P, Medico E, Campiglio M, Comoglio PM.
    Oncogene; 1994 Jun 01; 9(6):1691-7. PubMed ID: 8183564
    [Abstract] [Full Text] [Related]

  • 14. Ligand-independent oncogenic transformation by the EGF receptor requires kinase domain catalytic activity.
    Danielsen AJ, Maihle NJ.
    Exp Cell Res; 2002 Apr 15; 275(1):9-16. PubMed ID: 11925101
    [Abstract] [Full Text] [Related]

  • 15. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
    Rusyn EV, Reynolds ER, Shao H, Grana TM, Chan TO, Andres DA, Cox AD.
    Oncogene; 2000 Sep 28; 19(41):4685-94. PubMed ID: 11032018
    [Abstract] [Full Text] [Related]

  • 16. Oncogenic activation of the PDGF beta receptor by the transmembrane domain of p185neu*.
    Petti LM, Irusta PM, DiMaio D.
    Oncogene; 1998 Feb 19; 16(7):843-51. PubMed ID: 9484775
    [Abstract] [Full Text] [Related]

  • 17. GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation.
    Bai T, Luoh SW.
    Carcinogenesis; 2008 Mar 19; 29(3):473-9. PubMed ID: 17916906
    [Abstract] [Full Text] [Related]

  • 18. Dimer interface of transmembrane domains for neu/erbB-2 receptor dimerization and transforming activation: a model revealed by molecular dynamics simulations.
    Sajot N, Genest M.
    J Biomol Struct Dyn; 2001 Aug 19; 19(1):15-31. PubMed ID: 11565846
    [Abstract] [Full Text] [Related]

  • 19. Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes.
    Altenschmidt U, Kahl R, Moritz D, Schnierle BS, Gerstmayer B, Wels W, Groner B.
    Clin Cancer Res; 1996 Jun 19; 2(6):1001-8. PubMed ID: 9816261
    [Abstract] [Full Text] [Related]

  • 20. Selection and characterization of small random transmembrane proteins that bind and activate the platelet-derived growth factor beta receptor.
    Freeman-Cook LL, Dixon AM, Frank JB, Xia Y, Ely L, Gerstein M, Engelman DM, DiMaio D.
    J Mol Biol; 2004 May 14; 338(5):907-20. PubMed ID: 15111056
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.